Cover Image
市場調查報告書

癌症標靶治療藥市場及臨床考察 2015年

Cancer Targeted Therapy Market & Clinical Insight 2015

出版商 KuicK Research 商品編碼 327979
出版日期 內容資訊 英文 2900 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
癌症標靶治療藥市場及臨床考察 2015年 Cancer Targeted Therapy Market & Clinical Insight 2015
出版日期: 2015年04月08日 內容資訊: 英文 2900 Pages
簡介

本報告提供全球癌症標靶治療藥市場相關調查分析、癌症標靶藥物的分類、癌症標靶蛋白酪氨酸激酶、疫苗、癌症遺傳基因抑制劑、單株抗體的機制、各企業、適應症、相位的癌症標靶藥物的臨床實驗平台、開發平台中1,200個以上的癌症標靶藥物臨床考察、已上市癌症標靶藥物臨床考察、專利分析,及未來的癌症標靶藥物的展望等資料彙整,為您概述為以下內容。

第1章 癌症標靶藥物的簡介

第2章 癌症標靶藥物的必要性

第3章 癌症標靶藥物的分類

第4章 標靶藥物的癌症疫苗檢討

第5章 癌症疫苗的機制

  • 個體遺傳型癌症疫苗的機制
  • 細胞癌症疫苗的機制
  • 神經節苷脂抗原型癌症疫苗的機制
  • 肽癌症疫苗的機制
  • 腫瘤宿主相互作用癌症疫苗的機制

第6章 癌症標靶單株抗體的機制

  • 抗體標靶的腫瘤抗原
  • 臨床用抗體的開發
  • 補體依賴性細胞傷害 (CDC)
  • 信號傳達的變化

第7章 癌症標靶蛋白酪氨酸激酶療法的機制

第8章 癌症遺傳基因抑制劑的機制

第9章 全球癌症標靶藥物市場概要

  • 目前市場情況
  • 癌症標靶藥物的臨床實驗平台考察

第10章 全球癌症標靶藥物市場動態

  • 可喜的市場參數
  • 商業化的課題

第11章 癌症標靶藥物的未來展望

第12章 癌症標靶單株抗體的開發平台:各企業、適應症、相位

  • 不明
  • 研究
  • 前臨床
  • 臨床
  • 第一階段
  • 第1/2階段
  • 第二階段
  • 第2/3階段
  • 第三階段
  • 登記前
  • 登記後

第13章 已上市癌症單株抗體:各適應症、企業、國

第14章 全球癌症疫苗臨床實驗平台考察:各企業、適應症、相位

  • 不明
  • 研究
  • 前臨床
  • 臨床
  • 第一階段
  • 第1/2階段
  • 第二階段
  • 第2/3階段
  • 第三階段
  • 登記前
  • 登記後

第15章 已上市癌症疫苗臨床考察:各適應症、企業、國

第16章 癌症遺傳基因抑制劑的開發平台:各企業、適應症、相位

  • 癌症遺傳基因蛋白質抑制劑的開發平台
  • 癌症原遺傳基因蛋白質 c-bcl-2 抑制劑的開發平台b raf 抑制劑的開發平台
  • 癌症原遺傳基因蛋白質 c-kit 抑制劑的開發平台
  • 癌症原遺傳基因蛋白質 r-rel 抑制劑的開發平台
  • 癌症原遺傳基因蛋白質 c-akt 抑制劑的開發平台
  • 癌症原遺傳基因蛋白質 c met 抑制劑的開發平台
  • 癌症原遺傳基因蛋白質 c ret 抑制劑的開發平台
  • 癌症原遺傳基因蛋白質 c mdm2 抑制劑的開發平台
  • 癌症原遺傳基因蛋白質抑制劑的開發平台
  • 癌症原遺傳基因蛋白質 c-ets 抑制劑的開發平台
  • 癌症原遺傳基因蛋白質 c-fil-1 抑制劑的開發平台
  • 癌症原遺傳基因蛋白質 c pim 1 抑制劑的開發平台
  • 癌症原遺傳基因蛋白質 c-myc 抑制劑的開發平台
  • 多發性癌症遺傳基因抑制劑的開發平台

第17章 已上市癌症遺傳基因抑制劑:各企業、適應症

第18章 癌症標靶蛋白酪氨酸激酶臨床實驗:各企業、適應症、相位

  • 不明
  • 研究
  • 前臨床
  • 臨床
  • 第一階段
  • 第1/2階段
  • 第二階段
  • 第2/3階段
  • 第三階段
  • 登記前
  • 登記後

第19章 已上市癌症標靶蛋白酪氨酸激酶抑制劑

第20章 癌症標靶血管新生抑制劑的開發平台:各企業、相位、適應症

  • 不明
  • 研究
  • 前臨床
  • 臨床
  • 第一階段
  • 第1/2階段
  • 第二階段
  • 第2/3階段
  • 第三階段

第21章 已上市癌症標靶血管新生抑制劑

第22章 競爭情形

  • Advaxis
  • Bind Therapeutics
  • Boehringer Ingelheim
  • Bristol Mayer Squibb
  • Celldex Therapeutics
  • Dendreon Corporation
  • Eli Lily
  • GalaxoSmithKline
  • Galena Biopharma
  • Genetech
  • ImmunoCellular Therapeutics
  • ImmunoGen
  • Inovio Pharmaceuticals
  • Johnson & Johnson
  • NeoStem Oncology
  • NewLink Genetics
  • Northwest Biotherapeutics
  • Merck
  • Novartis
  • Peregrine Pharmaceuticals
  • Pfizer
  • Roche
  • Sanofi
  • Seattle Genetics
  • Teva

圖表清單

目錄

Cancer targeted therapeutics global market could be broadly divided into small and large molecules segments. Small molecules generate significant shares due to their sheer numbers as compared to large molecules cancer targeted therapeutics. Moreover, they have mature market and they could be considered as pioneer due to which they have more market penetration across the globe. Their prices have gone down because significant progress has been achieved in their drug design development, manufacturing and marketing. However, they have limited targeting efficacy and limited products could be used for multiple cancer indications. This scenario gave way to market introduction of large molecule cancer targeted therapeutics having better pharmacological profiles.

Small molecules cancer targeted therapeutics could be further divided into several categories depending upon cancer indications and target type. For instance, Gleevec by Novartis is tyrosine kinase inhibitor which is used in chronic myelogenous leukemia. Zelboraf by Roche is used for melanoma treatment which is a serine threonine kinase inhibitor. Multiple target inhibitors could also be observed in this segment which could be assigned to different cancer segments. Such capabilities allow them to erode profit margins of other drugs belonging to same and other cancer indications. It should also be noted that a single small molecule could fall in several segments due to which it could be used in lieu of similar drug. For instance, Lapatinib by GalaxoSmithKline acts on Her2/neu receptors and EGFR pathways related to breast cancer and lung cancer. Multiple target inhibitors contain both small and large molecule cancer targeted therapeutics. Various big pharmaceutical companies like Boehringer Ingelheim, Johnson & Johnson, Teva, Eli Lily and others are actively engaged in development of these molecules. Customizability of a molecule is among important factors that helps in increasing their market shares.

Large molecules like monoclonal antibodies are highly customizable due to which they could be formulated according to necessities of drug development program. Due to high versatility, they have been developed to target various molecules specific to particular cancer types. New target discovery could be considered as one of the most important factors affecting market growth of large molecule cancer targeted therapeutics. As compared to small molecule cancer targeted molecules, they have better pharmacological profiles and target binding efficacy due to which they would be able to occupy major market shares across the globe in coming years. They are still at emerging stages of industry life cycles due to which they offer significant marketing potential.

Clinical pipeline of innovative targeted therapeutics is increasing continuously due to which pharmaceutical companies would be able to generate more revenues. For instance, early diagnosis is a pre requisite of cancer patients undergoing cancer treatment. Paper carrying synthetic target molecule on surface is proposed to be used for identifying different cancers by soaking it in potential patient's urine. Such tests are expected to be marketed in underdeveloped countries where early cancer diagnosis tests are costly. Other uses of nanotechnology is being discovered by investigators so that they could directly target specific molecules without affecting neighboring cells. Further, new biomarkers are at various phases of clinical trials that would be able to introduce new cancer targeted therapeutics in global market in coming years.

Clinical Insight on Cancer Targeted Therapies Pipeline Covered in Report:

  • Cancer Targeted Tyrosine Kinase Inhibitors Pipeline: 388 TKI
  • Cancer Targeted Angiogenesis Inhibitors Pipeline: 166 Angiogenesis Inhibitors
  • Cancer Vaccines Pipeline: 289 Cancer Vaccines
  • Cancer Targeted Monoclonal Antibodies: 605 mAb
  • Oncogene Inhibitors Pipeline: 185 oncogene inhibitors

"Cancer Targeted Therapy Market & Clinical Insight" Report Highlight:

  • Introduction & Categorization of Cancer Targeted Therapies
  • Mechanism of Cancer Targeted Tyrosine Kinase, Vaccines, Oncogenes Inhibitors, Monoclonal Antibodies
  • Cancer Targeted Therapy Clinical Pipeline by Company, Indication & Phase
  • Clinical Insight on More Than 1200 Cancer Targeted Therapies in Pipeline
  • Clinical Insight & Patent Analysis of Marketed Cancer Targeted Therapies
  • Global Cancer Targeted Therapeutics Market Dynamics
  • Future Prospects of Cancer Targeted Therapies

Table of Contents

1. Introduction to Cancer Targeted Therapeutics

2. Need for Cancer Targeted Therapeutics

3. Categorization of Cancer Targeted Therapies

4. Consideration of Cancer Vaccines as Targeted Therapeutics

5. Mechanism of Cancer Vaccines

  • 5.1 Idiotype Cancer Vaccine Mechanism
  • 5.2 Cellular Cancer Vaccines Mechanism
  • 5.3 Ganglioside Antigens based Cancer Vaccines Mechanism
  • 5.4 Peptide Cancer Vaccine Mechanism
  • 5.5 Tumor Host Interaction Cancer Vaccine Mechanism

6. Mechanisms of Cancer Targeted Monoclonal Antibodies

  • 6.1 Tumor Antigens as Targets of Antibodies
  • 6.2 Development of Antibodies for Clinical Purposes
  • 6.3 Complement Dependent Cytotoxicity (CDC)
  • 6.4 Signal Transduction Changes

7. Mechanism of Cancer Targeted Tyrosine Kinase Therapeutics

8. Mechanism of Oncogene Inhibitors

9. Global Cancer Targeted Therapy Market Overview

  • 9.1 Current Market Scenario
  • 9.2 Cancer Targeted Therapy Clinical Pipeline Insight

10. Global Cancer Targeted Therapeutics Market Dynamics

  • 10.1 Favorable Market Parameters
  • 10.2 Commercialization Challenges

11. Future Prospects of Cancer Targeted Therapeutics

12. Cancer Targeted Monoclonal Antibodies Pipeline by Company, Indication & Phase

  • 12.1 Unknown
  • 12.2 Research
  • 12.3 Preclinical
  • 12.4 Clinical
  • 12.5 Phase I
  • 12.6 Phase I/II
  • 12.7 Phase II
  • 12.8 Phase II/III
  • 12.9 Phase III
  • 12.10 Preregistration
  • 12.11 Registered

13. Marketed Cancer Monoclonal Antibodies by Indication, Company & Country

14. Global Cancer Vaccines Clinical Pipeline Insight by Company, Indication & Phase

  • 14.1 Unknown
  • 14.2 Research
  • 14.3 Preclinical
  • 14.4 Clinical
  • 14.5 Phase-I
  • 14.6 Phase-I/II
  • 14.7 Phase-II
  • 14.8 Phase-II/III
  • 14.9 Phase-III
  • 14.10 Preregistration
  • 14.11 Registered

15. Marketed Cancer Vaccines Clinical Insight by Indication, Company & Country

16. Oncogene Inhibitors Pipeline by Company, Indication & Phase

  • 16.1 Oncogene Protein Inhibitors Pipeline
  • 16.2 Proto-Oncogene Protein c-bcl-2 Inhibitors Pipeline
  • 16.3 Proto Oncogene Protein b raf Inhibitors Pipeline
  • 16.4 Proto Oncogene Protein c-kit Inhibitors Pipeline
  • 16.5 Proto-Oncogene Protein c-rel Inhibitors Pipeline
  • 16.6 Proto Oncogene Protein c-akt Inhibitors Pipeline
  • 16.7 Proto Oncogene Protein c met Inhibitors Pipeline
  • 16.8 Proto Oncogene Protein c ret Inhibitors Pipeline
  • 16.9 Proto-Oncogene Protein c mdm2 Inhibitors Pipeline
  • 16.10 Proto-Oncogene Protein Inhibitors Pipeline
  • 16.11 Proto-Oncogene-Protein-c-ets Inhibitors Pipeline
  • 16.12 Proto-Oncogene Protein c-fli-1 Inhibitors Pipeline
  • 16.13 Proto Oncogene Proteins c pim 1 Inhibitors Pipeline
  • 16.14 Proto Oncogene Protein c-myc Inhibitors Pipeline
  • 16.15 Multiple Oncogene Inhibitors Pipeline

17. Marketed Oncogene Inhibitors by Company & Indication

18. Cancer Targeted Tyrosine Kinase Clinical Trial by Company, Indication & Phase

  • 18.1 Unknown
  • 18.2 Research
  • 18.3 Preclinical
  • 18.4 Clinical
  • 18.5 Phase-I
  • 18.6 Phase-I/II
  • 18.7 Phase-II
  • 18.8 Phase-II/III
  • 18.9 Phase-III
  • 18.10 Preregistration
  • 18.11 Registered

19. Marketed Cancer Targeted Tyrosine Kinase Inhibitors

20. Cancer Targeted Angiogenesis Inhibitors Therapy Pipeline by Company, Phase & Indication

  • 20.1 Unknown
  • 20.2 Research
  • 20.3 Preclinical
  • 20.4 Clinical
  • 20.5 Phase-I
  • 20.6 Phase-I/II
  • 20.7 Phase-II
  • 20.8 Phase-III

21. Marketed Cancer Targeted Angiogenesis Inhibitors

22. Competitive Landscape

  • 22.1 Advaxis
  • 22.2 Bind Therapeutics
  • 22.3 Boehringer Ingelheim
  • 22.4 Bristol Mayer Squibb
  • 22.5 Celldex Therapeutics
  • 22.6 Dendreon Corporation
  • 22.7 Eli Lily
  • 22.8 GalaxoSmithKline
  • 22.9 Galena Biopharma
  • 22.10 Genetech
  • 22.11 ImmunoCellular Therapeutics
  • 22.12 ImmunoGen
  • 22.13 Inovio Pharmaceuticals
  • 22.14 Johnson & Johnson
  • 22.15 NeoStem Oncology
  • 22.16 NewLink Genetics
  • 22.17 Northwest Biotherapeutics
  • 22.18 Merck
  • 22.19 Novartis
  • 22.20 Peregrine Pharmaceuticals
  • 22.21 Pfizer
  • 22.22 Roche
  • 22.23 Sanofi
  • 22.24 Seattle Genetics
  • 22.25 Teva

List of Tables

  • Table 2-1: Difference between Chemotherapeutics & Targeted Therapeutics
  • Table 3-1: Suffix used for Targeted Therapeutics
  • Table 3-2: Naming of Small Molecule Targeted Therapeutics
  • Table 3-3: Nomenclature of Monoclonal Antibodies
  • Table 9-1: Breast Cancer Targeted Therapeutics
  • Table 9-2: Lung Cancer Targeted Therapeutics

List of Figures

  • Figure 1-1: Uses of Pharmacogenomics
  • Figure 1-2: Developmental Stages of Targeted Therapeutics
  • Figure 1-3: Cancer Target Identification Techniques
  • Figure 1-4: Genetic Anomalies Classification
  • Figure 1-5: Mechanism of Cancer Targeted Therapeutics
  • Figure 1-6:Improvements Required for Cancer Targeted Therapies
  • Figure 2-1: Objectives of Cancer Targeted Therapeutics
  • Figure 2-2: Benefits of Cancer Targeted Therapeutics
  • Figure 3-1: Categorization of Cancer Targeted Therapeutics on the Basis of Molecular Size
  • Figure 3-2: Features of Cancer Targeted Small Molecules Drugs
  • Figure 3-3: Features of Cancer Targeting Antibodies
  • Figure 3-4: Classification of Cancer Targeted Therapies on the Basis of their Mechanism
  • Figure 4-1: Classification of Cancer Vaccines
  • Figure 4 2: Distinction of Cancer Vaccines
  • Figure 5-1: Classification of Different Types of Cancer vaccines
  • Figure 7-1: Benefits of Cancer Tyrosine Kinase Targeted Therapeutics
  • Figure 7-2: Classification of Tyrosine Kinase
  • Figure 7-3: Mechanism of Cancer Tyrosine Kinase Targeted Therapeutics
  • Figure 7-4: Mechanism of VEGFR
  • Figure 8-1: Activation of Proto-Oncogenes to Oncogenes
  • Figure 8-2:Benefits of Oncogene Inhibitors
  • Figure 8-3: Mechanism of Crizotinib
  • Figure 8-4: Mechanism of Vemurafenib
  • Figure 8-5: Mechanism of Vorinostat
  • Figure 9-1: Cancer Monoclonal Antibodies Therapy Pipeline by Phase (%), 2015
  • Figure 9-2: Cancer Monoclonal Antibodies Therapy Pipeline by Phase (Number), 2015
  • Figure 9-3: Global Cancer Vaccines Clinical Pipeline by Phase (%), 2015
  • Figure 9-4: Global Cancer Vaccines Clinical Pipeline by Phase (Number), 2015
  • Figure 9-5: Cancer Tyrosine Kinase Inhibitors Pipeline by Phase (%), 2015
  • Figure 9-6: Cancer Tyrosine Kinase Inhibitors Pipeline by Phase (Number), 2015
  • Figure 9-7: Proto-Oncogene Protein c-bcl-2 Inhibitors Pipeline by Phase(%), 2015
  • Figure 9-8: Proto-Oncogene Protein c-bcl-2 Inhibitors Pipeline by Phase(Number), 2015
  • Figure 9-9: Proto Oncogene Protein b raf Inhibitors Pipeline by Phase(%), 2015
  • Figure 9-10: Proto Oncogene Protein b raf Inhibitors Pipeline by Phase(Number), 2015
  • Figure 9-11: Proto Oncogene Protein c-kit Inhibitors Pipeline by Phase(%), 2015
  • Figure 9-12: Proto Oncogene Protein c-kit Inhibitors Pipeline by Phase(Number), 2015
  • Figure 9-13: Proto Oncogene Protein c-akt Inhibitors Pipeline by Phase(%), 2015
  • Figure 9-14: Proto Oncogene Protein c-akt Inhibitors Pipeline by Phase(Number), 2015
  • Figure 9-15: Proto Oncogene Protein c met Inhibitors Pipeline by Phase(%), 2015
  • Figure 9-16: Proto Oncogene Protein c met Inhibitors Pipeline by Phase(Number), 2015
  • Figure 9-17: Proto Oncogene Protein c ret Inhibitors Pipeline by Phase(%), 2015
  • Figure 9-18: Proto Oncogene Protein c ret Inhibitors Pipeline by Phase(Number), 2015
  • Figure 9-19: Proto -Oncogene Protein c mdm2 Inhibitors Pipeline by Phase(%), 2015
  • Figure 9-20: Proto -Oncogene Protein c mdm2 Inhibitors Pipeline by Phase(Number), 2015
  • Figure 9-21: Proto Oncogene Protein c pim 1 Inhibitors Pipeline by Phase(%), 2015
  • Figure 9-22: Proto Oncogene Protein c pim 1 Inhibitors Pipeline by Phase(Number), 2015
  • Figure 9-23: Proto Oncogene Protein c-myc Inhibitors Pipeline by Phase(%), 2015
  • Figure 9-24: Proto Oncogene Protein c-myc Inhibitors Pipeline by Phase(Number), 2015
  • Figure 9-25: Multiple Oncogene Inhibitors Pipeline by Phase(%), 2015
  • Figure 9-26: Multiple Oncogene Inhibitors Pipeline by Phase(number), 2015
  • Figure 9-27: Angienesis Inhibitors Pipeline by Phase (%), 2015
  • Figure 9-28: Angienesis Inhibitors Pipeline by Phase (Number), 2015
  • Figure 22-1: Advaxis Clinical Pipeline
  • Figure 22-2: Celldex Therapeutics Clinical Pipeline
  • Figure 22-3: Galena Biopharma Clinical Pipeline
  • Figure 22-4: ImmunoCellular Therapeutics Clinical Pipeline
  • Figure 22-5: ImmunoGen Clinical Pipeline
  • Figure 22-6: Inovio Pharmaceuticals Clinical Pipeline
  • Figure 22-7: NewLink Genetics Corporation Clinical Pipeline
  • Figure 22-8: Northwest Biotherapeutics Clinical Pipeline
  • Figure 22-9: Peregrine Pharmaceuticals Clinical Pipeline
  • Figure 22-10: Seattle Genetics Clinical Pipeline
Back to Top